BioCardia Inc.

0.6723+0.0511+8.23%Vol 312.16K1Y Perf -65.68%
Dec 1st, 2023 16:00 DELAYED
BID0.6400 ASK0.6723
Open0.6120 Previous Close0.6212
Pre-Market- After-Market0.66
 - -  -0.02 -2.57%
Target Price
6.33 
Analyst Rating
Moderate Buy 2.00
Potential %
841.54 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
     38.06
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★+     47.53
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
12.20 
Earnings Rating
Market Cap14.53M 
Earnings Date
8th Nov 2023
Alpha-0.05 Standard Deviation0.24
Beta1.16 

Today's Price Range

0.59500.6765

52W Range

0.36002.92

5 Year PE Ratio Range

-2.70-3.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-12.42%
1 Month
63.95%
3 Months
-20.25%
6 Months
-65.49%
1 Year
-65.68%
3 Years
-74.85%
5 Years
-96.17%
10 Years
-94.77%

TickerPriceChg.Chg.%
BCDA0.67230.05118.23
AAPL191.241.29000.68
GOOG133.32-0.6000-0.45
MSFT374.51-4.4000-1.16
XOM102.990.25000.24
WFC45.020.43000.96
JNJ158.383.72002.41
FB196.640.99000.51
GE122.500.70000.57
JPM156.840.76000.49
Financial StrengthValueIndustryS&P 500US Markets
1.90
1.90
0.25
0.42
-13 997.00
Leverage Ratio 1.80
ProfitabilityValueIndustryS&P 500US Markets
100.00
-931.10
-925.40
-4 321.50
-
RevenueValueIndustryS&P 500US Markets
1.25M
0.06
7.01
2.06
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.15-0.17-13.33
Q01 2023-0.13-0.17-30.77
Q04 2022-0.18-0.1611.11
Q03 2022-0.23-0.1726.09
Q02 2022-0.28-0.1450.00
Q01 2022-0.15-0.19-26.67
Q04 2021-0.21-0.210.00
Q03 2021--0.16-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.12
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume312.16K
Shares Outstanding21.62K
Shares Float12.34M
Trades Count978
Dollar Volume197.79K
Avg. Volume715.05K
Avg. Weekly Volume748.98K
Avg. Monthly Volume977.71K
Avg. Quarterly Volume418.46K

BioCardia Inc. (NASDAQ: BCDA) stock closed at 0.6212 per share at the end of the most recent trading day (a -8.65% change compared to the prior day closing price) with a volume of 490.27K shares and market capitalization of 14.53M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 24 people. BioCardia Inc. CEO is Peter Altman.

The one-year performance of BioCardia Inc. stock is -65.68%, while year-to-date (YTD) performance is -70.28%. BCDA stock has a five-year performance of -96.17%. Its 52-week range is between 0.36 and 2.9199, which gives BCDA stock a 52-week price range ratio of 12.20%

BioCardia Inc. currently has a PE ratio of -3.40, a price-to-book (PB) ratio of 11.69, a price-to-sale (PS) ratio of 36.84, a price to cashflow ratio of 26.20, a PEG ratio of -, a ROA of -103.44%, a ROC of -118.83% and a ROE of -159.65%. The company’s profit margin is -%, its EBITDA margin is -925.40%, and its revenue ttm is $1.25 Million , which makes it $0.06 revenue per share.

Of the last four earnings reports from BioCardia Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. BioCardia Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BioCardia Inc. is Moderate Buy (2), with a target price of $6.33, which is +841.54% compared to the current price. The earnings rating for BioCardia Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioCardia Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioCardia Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.89, ATR14 : 0.09, CCI20 : 25.36, Chaikin Money Flow : -0.15, MACD : 0.06, Money Flow Index : 54.88, ROC : 59.28, RSI : 53.72, STOCH (14,3) : 32.57, STOCH RSI : 0.00, UO : 58.49, Williams %R : -67.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioCardia Inc. in the last 12-months were: Altman Peter (Buy at a value of $9 920), Phillip Frost (Buy at a value of $1 000 000)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

BioCardia Inc.

BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack.

CEO: Peter Altman

Telephone: +1 650 226-0120

Address: 125 Shoreway Road, San Carlos 94070, CA, US

Number of employees: 24

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

55%45%

Bearish Bullish

60%40%

 

TipRanks News for BCDA


News

Stocktwits